AG
STML

Aperio Group’s Stemline Therapeutics, Inc. STML Stock Holding History

Aperio Group’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-321
Closed -$5K – 2971
2019
Q2 		$5K Buy
+321
New +$4.64K ﹤0.01% 2867

Other funds holding STML

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Aperio Group's STML Position: Q3 2019 in Review

Aperio Group sold out of Stemline Therapeutics, Inc. (STML) in Q3 2019, closing a stake of 321 shares — an estimated $5K sold.

Aperio Group first reported a position in STML in Q2 2019 and held it in 1 quarter. The position peaked at $5K in Q2 2019. 100 funds tracked by Wall St. Rank hold STML as of Q3 2019.

  • Aperio Group reported no remaining Stemline Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
  • Aperio Group sold 321 Stemline Therapeutics, Inc. shares in Q3 2019, an estimated $5K.
  • Aperio Group first reported a position in Stemline Therapeutics, Inc. in Q2 2019 and held it in 1 quarter.
  • Aperio Group's Stemline Therapeutics, Inc. position peaked at $5K in Q2 2019.
  • 100 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q3 2019.

Based on Aperio Group's 13F filing for Q3 2019, filed 6 Nov 2019.